🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 25% of ingredients have research evidence
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

5 Capsule(s) Serving Size
15 Servings
Botanical with Nutrients Product Type
25% Evidence Coverage

Supplement Facts — Evidence Check

Calories
15 Calorie(s)
Total Fat
1.67 Gram(s) (1% DV)
Enzogenol dry extract
1000 mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 1666mg UL 3000mg

Other Ingredients

Gelatine Glycerine Water Beeswax Sorbitol natural Vitamin E Soybean Lecithin

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (99% of products) Structure/Function (86% of products) Nutrient (79% of products) Qualified Health (13% of products) Approved Health (2% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions: Take this number of capsules as one dose in the morning. Assist dose - adults: 5, children: 2. Maintenance dose - adults: 2-3, children: 1; or as directed by your doctor.

⚠️ Warnings & Precautions

Keep out of reach of children.

🧪 Formulation Notes

Scientifically researched brain function support for cognitive performance, helping you stay alert and focused.

New Zealand pine bark extract with added DHA omega-3

Made in New Zealand from local and imported ingredients.

Additional Information

Store in a dry place below 20 degrees C. Keep tightly closed.

See our other products at enzo.co.nz Ph: 0800 436 964 (NZ only)

Product Details

UPC / SKU 9 421008 082460
DSLD Entry Date 2022-05-19
Product Type Botanical with Nutrients
Form Capsule
Brand ENZO
DSLD ID 264778
Data Updated 2026-04-11

Research Evidence

495 Research Sources
56 Avg Quality Score
222 Meta Analysis
104 Clinical Trial
72 Rct
69 Systematic Review
11 Guideline
5 Cochrane Review
5 Regulatory Source
3 Narrative Review
1 Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
View all evidence for Omega 3 →

Compare Similar Products

View all Omega 3 products →